Product Description: (R)-Vorbipiprant ((R)-CR6086) is an orally active antagonist for prostaglandin E2 receptor 4 (EP4) with Ki of 16.6 nM for human EP4. (R)-Vorbipiprant inhibits PGE2 (HY-101952)-induced cAMP production with an IC50 of 22 nM. (R)-Vorbipiprant exhibits immunomodulatory and anti-angiogenic activities, and ameliorates the collagen-induced arthritis in mice[1].
Applications: COVID-19-immunoregulation
Formula: C26H27F3N2O3
References: [1]Caselli G, et al., Pharmacological characterisation of CR6086, a potent prostaglandin E2 receptor 4 antagonist, as a new potential disease-modifying anti-rheumatic drug. Arthritis Res Ther. 2018 Mar 1;20(1):39.
CAS Number: 2502965-92-4
Molecular Weight: 472.50
Research Area: Inflammation/Immunology
Target: Prostaglandin Receptor